Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...

Google Maps is one of the most useful navigational tools on Android. It enables people to preview a trip and plan for obstacles. However, knowing how to find where you are right now on the map is ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

Amgen reported strong financial results for the fourth quarter of 2024, with revenues of $9.09 billion and earnings per share (EPS) of $5.31, surpassing analyst expectations. The company’s performance ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best retirement stocks to buy according to hedge funds. After much suspense, the US Federal ...

The FDA has approved AstraZeneca and Amgen's severe asthma hope tezepelumab, exonerating the drugmakers' decision to press ahead with a regulatory filing despite a failed phase 3 trial.

Amgen’s Wezlana (ustekinumab-auub) launched in January. Wezlana is available only through Optum, a division of UnitedHealth Group. An Optum spokesperson said in an email that Nuvaila has exclusivity ...